Patent ID: 8278348

Claim:
A method of inhibiting vacuolar-type (H+)-ATPase in a patient in need thereof, the method comprising administering to the patient a vacuolar-type (H+)-ATPase-inhibiting effective amount of at least one compound of the formula: wherein: R 1 is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R 1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR 1a , CO 2 R 1a , and OC(O)R 1a , wherein R 1a is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof; R 2 -R 8 are the same or different and each is R 10 , C(O)R 10 , SO 3 R 10 , or SO 2 R 10 , wherein R 10 is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R 10 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR 10a , CO 2 R 10a and OC(O)R 10a , wherein R 10a is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof; and R 9 is a substituent of the formula: wherein the R 9a substituents are the same or different and each is R 11 , C(O)R 11 , or SO 2 R 11 , wherein R 11 is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R 11 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR 11a , CO 2 R 11a and OC(O)R 11a , wherein R 11a is H, a straight-chain or branched C 1-30 saturated alkyl, a straight-chain or branched C 2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof; wherein R 1a , R 10a and R 11a are unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen, an oxo, and a hydroxyl; or a pharmaceutically acceptable salt thereof, whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.